Literature DB >> 27427455

The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia.

Frederick L Altice1, Lyuba Azbel2, Jack Stone3, Ellen Brooks-Pollock3, Pavlo Smyrnov4, Sergii Dvoriak5, Faye S Taxman6, Nabila El-Bassel7, Natasha K Martin8, Robert Booth9, Heino Stöver10, Kate Dolan11, Peter Vickerman3.   

Abstract

Despite global reductions in HIV incidence and mortality, the 15 UNAIDS-designated countries of Eastern Europe and Central Asia (EECA) that gained independence from the Soviet Union in 1991 constitute the only region where both continue to rise. HIV transmission in EECA is fuelled primarily by injection of opioids, with harsh criminalisation of drug use that has resulted in extraordinarily high levels of incarceration. Consequently, people who inject drugs, including those with HIV, hepatitis C virus, and tuberculosis, are concentrated within prisons. Evidence-based primary and secondary prevention of HIV using opioid agonist therapies such as methadone and buprenorphine is available in prisons in only a handful of EECA countries (methadone or buprenorphine in five countries and needle and syringe programmes in three countries), with none of them meeting recommended coverage levels. Similarly, antiretroviral therapy coverage, especially among people who inject drugs, is markedly under-scaled. Russia completely bans opioid agonist therapies and does not support needle and syringe programmes-with neither available in prisons-despite the country's high incarceration rate and having the largest burden of people with HIV who inject drugs in the region. Mathematical modelling for Ukraine suggests that high levels of incarceration in EECA countries facilitate HIV transmission among people who inject drugs, with 28-55% of all new HIV infections over the next 15 years predicted to be attributable to heightened HIV transmission risk among currently or previously incarcerated people who inject drugs. Scaling up of opioid agonist therapies within prisons and maintaining treatment after release would yield the greatest HIV transmission reduction in people who inject drugs. Additional analyses also suggest that at least 6% of all incident tuberculosis cases, and 75% of incident tuberculosis cases in people who inject drugs are due to incarceration. Interventions that reduce incarceration itself and effectively intervene with prisoners to screen, diagnose, and treat addiction and HIV, hepatitis C virus, and tuberculosis are urgently needed to stem the multiple overlapping epidemics concentrated in prisons.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27427455      PMCID: PMC5087988          DOI: 10.1016/S0140-6736(16)30856-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  96 in total

Review 1.  Implementation of harm reduction in Central and Eastern Europe and Central Asia.

Authors:  Anya Sarang; Raminta Stuikyte; Roman Bykov
Journal:  Int J Drug Policy       Date:  2006-12-19

Review 2.  Drug use as a driver of HIV risks: re-emerging and emerging issues.

Authors:  Nabila El-Bassel; Stacey A Shaw; Anindita Dasgupta; Steffanie A Strathdee
Journal:  Curr Opin HIV AIDS       Date:  2014-03       Impact factor: 4.283

3.  Tackling the spread of drug-resistant tuberculosis in Europe.

Authors:  Ibrahim Abubakar; Masoud Dara; Davide Manissero; Alimuddin Zumla
Journal:  Lancet       Date:  2011-09-14       Impact factor: 79.321

Review 4.  What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010-2012? A review of the six highest burden countries.

Authors:  Louisa Degenhardt; Bradley M Mathers; Andrea L Wirtz; Daniel Wolfe; Adeeba Kamarulzaman; M Patrizia Carrieri; Steffanie A Strathdee; Kasia Malinowska-Sempruch; Michel Kazatchkine; Chris Beyrer
Journal:  Int J Drug Policy       Date:  2013-09-04

5.  HIV testing and counselling in Estonian prisons, 2012 to 2013: aims, processes and impacts.

Authors:  K Kivimets; A Uuskula
Journal:  Euro Surveill       Date:  2014-11-27

6.  Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial.

Authors:  Josiah D Rich; Michelle McKenzie; Sarah Larney; John B Wong; Liem Tran; Jennifer Clarke; Amanda Noska; Manasa Reddy; Nickolas Zaller
Journal:  Lancet       Date:  2015-05-28       Impact factor: 79.321

7.  Predictors of HIV sero-status among drug injectors at three Ukraine sites.

Authors:  Robert E Booth; Carol F Kwiatkowski; John T Brewster; Larisa Sinitsyna; Sergey Dvoryak
Journal:  AIDS       Date:  2006-11-14       Impact factor: 4.177

8.  Intersecting epidemics of HIV, HCV, and syphilis among soon-to-be released prisoners in Kyrgyzstan: Implications for prevention and treatment.

Authors:  Lyuba Azbel; Maxim Polonsky; Martin Wegman; Natalya Shumskaya; Ainura Kurmanalieva; Akylbek Asanov; Jeffrey A Wickersham; Sergii Dvoriak; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2016-06-11

Review 9.  A review of medical and substance use co-morbidities in Central Asian prisons: implications for HIV prevention and treatment.

Authors:  Panagiotis Vagenas; Lyuba Azbel; Maxim Polonsky; Nina Kerimi; Mirlan Mamyrov; Sergey Dvoryak; Frederick L Altice
Journal:  Drug Alcohol Depend       Date:  2013-08-09       Impact factor: 4.492

10.  Elevated HIV risk behaviour among recently incarcerated injection drug users in a Canadian setting: a longitudinal analysis.

Authors:  M-J S Milloy; Jane Buxton; Evan Wood; Kathy Li; Julio S G Montaner; Thomas Kerr
Journal:  BMC Public Health       Date:  2009-05-27       Impact factor: 3.295

View more
  90 in total

1.  Estimating HIV and HCV prevalence among people who inject drugs in 5 Ukrainian cities using stratification-based respondent driven and random sampling.

Authors:  Alexei Zelenev; Portia Shea; Alyona Mazhnaya; Anna Meteliuk; Iryna Pykalo; Ruthanne Marcus; Tatiana Fomenko; Tatiana Prokhorova; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2018-11-29

2.  Differences by sex in associations between injection drug risks and drug crime conviction among people who inject drugs in Almaty, Kazakhstan.

Authors:  Phillip L Marotta; Louisa Gilbert; Assel Terlikbayeva; Elwin Wu; Nabila El-Bassel
Journal:  Int J Drug Policy       Date:  2018-09-13

3.  Effect of expanding opioid agonist therapies on the HIV epidemic and mortality in Ukraine: a modelling study.

Authors:  Jiale Tan; Frederick L Altice; Lynn M Madden; Alexei Zelenev
Journal:  Lancet HIV       Date:  2019-12-23       Impact factor: 12.767

4.  Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine.

Authors:  Ruthanne Marcus; Iuliia Makarenko; Alyona Mazhnaya; Alexei Zelenev; Maxim Polonsky; Lynn Madden; Sergii Filippovych; Sergii Dvoriak; Sandra A Springer; Frederick L Altice
Journal:  Drug Alcohol Depend       Date:  2017-08-05       Impact factor: 4.492

5.  Sexual Risks and Policing among Male Migrant and Non-migrant Market Vendors in Central Asia.

Authors:  Phillip Marotta; Nabila El-Bassel; Assel Terlikbayeva; Gaukhar Mergenova; Sholpan Primbetova; Elwin Wu; Louisa Gilbert
Journal:  J Urban Health       Date:  2018-02       Impact factor: 3.671

6.  Design and implementation of a factorial randomized controlled trial of methadone maintenance therapy and an evidence-based behavioral intervention for incarcerated people living with HIV and opioid dependence in Malaysia.

Authors:  Alexander R Bazazi; Jeffrey A Wickersham; Martin P Wegman; Gabriel J Culbert; Veena Pillai; Roman Shrestha; Haider Al-Darraji; Michael M Copenhaver; Adeeba Kamarulzaman; Frederick L Altice
Journal:  Contemp Clin Trials       Date:  2017-05-04       Impact factor: 2.226

7.  Retention in medication-assisted treatment programs in Ukraine-Identifying factors contributing to a continuing HIV epidemic.

Authors:  Kostyantyn Dumchev; Sergii Dvoryak; Olena Chernova; Olga Morozova; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2017-08-08

Review 8.  Global opioid agonist treatment: a review of clinical practices by country.

Authors:  Harry Jin; Brandon D L Marshall; Louisa Degenhardt; John Strang; Matt Hickman; David A Fiellin; Robert Ali; Julie Bruneau; Sarah Larney
Journal:  Addiction       Date:  2020-05-19       Impact factor: 6.526

9.  Using Mixed Methods and Multidisciplinary Research to Strengthen Policy Assessments Focusing on Populations at High Risk for Sexually Transmitted Diseases.

Authors:  Kelly Thompson; Ryan Cramer; Archana Bodas LaPollo; Sarah Hexem Hubbard; Harrell W Chesson; Jami S Leichliter
Journal:  Public Health Rep       Date:  2020 Jul/Aug       Impact factor: 2.792

10.  Perceptions of Health-Related Community Reentry Challenges among Incarcerated Drug Users in Azerbaijan, Kyrgyzstan, and Ukraine.

Authors:  Julia Rozanova; Olga Morozova; Lyuba Azbel; Chethan Bachireddy; Jacob M Izenberg; Tetiana Kiriazova; Sergiy Dvoryak; Frederick L Altice
Journal:  J Urban Health       Date:  2018-08       Impact factor: 3.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.